“Safeguarding the well being and security of Americans could be the FDA’s maximum priority, and We are going to continue to be vigilant and connect about products and solutions and firms that location U.S. shoppers in danger,” reported Donald D. Ashley, J.D., director from the Business of Compliance in the FDA’s Center for Drug Evaluation a